Surfome Analysis as a Fast Track to Vaccine Discovery

Safe recombinant vaccines, based on a small number of antigenic proteins, are emerging as the most attractive, cost-effective solution against infectious diseases. In the present work, we confirmed previous data from our laboratory showing that whole viable bacterial cell treatment with proteases followed by the identification of released peptides by mass spectrometry is the method of choice for the rapid and reliable identification of vaccine candidates in Gram-positive bacteria. When applied to the Group B Streptococcus COH1 strain, 43 surface-associated proteins were identified, including all the protective antigens described in the literature as well as a new protective antigen, the cell wall-anchored protein SAN_1485 belonging to the serine-rich repeat protein family. This strategy overcomes the difficulties so far encountered in the identification of novel vaccine candidates and speeds up the entire vaccine discovery process by reducing the number of recombinant proteins to be tested in the animal model.

[1]  G. Grandi,et al.  Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic Escherichia coli ΔtolR IHE3034 Mutant*S , 2008, Molecular & Cellular Proteomics.

[2]  R. Rappuoli,et al.  The value of vaccines , 2003, Nature Reviews Microbiology.

[3]  Edward N. Baker,et al.  Stabilizing Isopeptide Bonds Revealed in Gram-Positive Bacterial Pilus Structure , 2007, Science.

[4]  R. Rappuoli,et al.  Group B Streptococcus: global incidence and vaccine development , 2006, Nature Reviews Microbiology.

[5]  O. Schneewind,et al.  Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.

[6]  Darren R Flower,et al.  LIPPRED: A web server for accurate prediction of lipoprotein signal sequences and cleavage sites , 2006, Bioinformation.

[7]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  I. Margarit,et al.  Identification of novel genomic islands coding for antigenic pilus‐like structures in Streptococcus agalactiae , 2006, Molecular microbiology.

[9]  L. Brady,et al.  A unique serine-rich repeat protein (Srr-2) and novel surface antigen (epsilon) associated with a virulent lineage of serotype III Streptococcus agalactiae. , 2006, Microbiology.

[10]  G. Grandi,et al.  Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: Proteomic and immunological comparison with detergent‐derived outer membrane vesicles , 2006, Proteomics.

[11]  G. Bensi,et al.  Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome , 2006, Nature Biotechnology.

[12]  G. Grandi.  Genomics and proteomics in reverse vaccines. , 2005, Methods of biochemical analysis.

[13]  Jaideep P. Sundaram,et al.  Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Baker,et al.  Group B streptococcal infections in elderly adults. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  B. Spratt,et al.  Multilocus Sequence Typing of Swedish Invasive Group B Streptococcus Isolates Indicates a Neonatally Associated Genetic Lineage and Capsule Switching , 2005, Journal of Clinical Microbiology.

[16]  R. Rappuoli,et al.  Genome Analysis Reveals Pili in Group B Streptococcus , 2005, Science.

[17]  H. Tettelin,et al.  Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.

[18]  Martin Ester,et al.  Sequence analysis PSORTb v . 2 . 0 : Expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis , 2004 .

[19]  J. Wells,et al.  Characterization of a Novel Leucine-Rich Repeat Protein Antigen from Group B Streptococci That Elicits Protective Immunity , 2005, Infection and Immunity.

[20]  J. Eggert,et al.  A history of neonatal group B streptococcus with its related morbidity and mortality rates in the United States. , 2004, Journal of pediatric nursing.

[21]  N. Uldbjerg,et al.  Dynamics of Streptococcus agalactiae Colonization in Women during and after Pregnancy and in Their Infants , 2004, Journal of Clinical Microbiology.

[22]  S. Gill,et al.  Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens. , 2003, BioTechniques.

[23]  Philippe Glaser,et al.  Multilocus Sequence Typing System for Group B Streptococcus , 2003, Journal of Clinical Microbiology.

[24]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[25]  D. Shelver,et al.  A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen. , 2003, The Journal of clinical investigation.

[26]  J. Baseman,et al.  Elongation factor Tu and E1 β subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae , 2002, Molecular microbiology.

[27]  S. Olmsted,et al.  Immunization with C5a Peptidase or Peptidase-Type III Polysaccharide Conjugate Vaccines Enhances Clearance of Group B Streptococci from Lungs of Infected Mice , 2002, Infection and Immunity.

[28]  N. Charland,et al.  Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein , 2002, Infection and Immunity.

[29]  Johannes Söllner,et al.  Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Nogarotto,et al.  Genomic Approach for Analysis of Surface Proteins in Chlamydia pneumoniae , 2002, Infection and Immunity.

[31]  R. Rappuoli,et al.  Reverse vaccinology: a genome-based approach for vaccine development , 2002, Expert opinion on biological therapy.

[32]  G. Grandi,et al.  Antibacterial vaccine design using genomics and proteomics. , 2001, Trends in biotechnology.

[33]  S. Olmsted,et al.  Antibody against Surface-Bound C5a Peptidase Is Opsonic and Initiates Macrophage Killing of Group B Streptococci , 2001, Infection and Immunity.

[34]  J. Musser,et al.  Identification and Immunogenicity of Group AStreptococcus Culture Supernatant Proteins , 2000, Infection and Immunity.

[35]  V. Monnet,et al.  Streptococcus thermophilus Cell Wall-Anchored Proteinase: Release, Purification, and Biochemical and Genetic Characterization , 2000, Applied and Environmental Microbiology.

[36]  I. Charlebois,et al.  Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity , 2000, Infection and Immunity.

[37]  V. Clark,et al.  Role of Ribosomal Protein L12 in Gonococcal Invasion of Hec1B Cells , 2000, Infection and Immunity.

[38]  G. Tyrrell,et al.  Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators. , 2000, The Journal of infectious diseases.

[39]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[40]  R. Rappuoli.  Reverse vaccinology : Genomics , 2000 .

[41]  G. Lindahl,et al.  Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. , 1999, Vaccine.

[42]  R. Lloubès,et al.  Escherichia coli tol-pal Mutants Form Outer Membrane Vesicles , 1998, Journal of bacteriology.

[43]  P. Brennan,et al.  Mapping and Identification of the Major Cell Wall-Associated Components of Mycobacterium leprae , 1998, Infection and Immunity.

[44]  A. Schuchat,et al.  Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. , 1998, The Journal of infectious diseases.

[45]  G. Splitter,et al.  Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. , 1997, Vaccine.

[46]  I. Padmalayam,et al.  The 75-kilodalton antigen of Bartonella bacilliformis is a structural homolog of the cell division protein FtsZ , 1997, Journal of bacteriology.

[47]  G. Lindahl,et al.  Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha , 1996, Infection and immunity.

[48]  A. Schuchat,et al.  Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. , 1994, Epidemiologic reviews.

[49]  G. Lindahl,et al.  Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.

[50]  D. Kasper,et al.  Neonatal mouse model of group B streptococcal infection. , 1992, The Journal of infectious diseases.

[51]  H. C. Wu,et al.  Physiological characterization of an Escherichia coli mutant altered in the structure of murein lipoprotein , 1978, Journal of bacteriology.

[52]  V. Dole,et al.  THE PROPERTIES OF T ANTIGENS EXTRACTED FROM GROUP A HEMOLYTIC STREPTOCOCCI , 1946, The Journal of experimental medicine.